Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Mavoglurant

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    STALICLA Initiates US DDI Study Of STP7 For Cocaine Use Disorder
    STALICLA Initiates US DDI Study Of STP7 For Cocaine Use Disorder

    02 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/02/2874183/0/en/STALICLA-initiates-U-S-Phase-3-enabling-DDI-study-of-STP7-Mavoglurant-to-treat-cocaine-use-disorder.html

    GLOBENEWSWIRE
    02 May 2024
    Share Share
    STALICLA signs CRADA with US NIDA to cover PIII development of mavoglurant
    STALICLA signs CRADA with US NIDA to cover PIII development of mavoglurant

    08 Mar 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/03/08/2622807/0/en/STALICLA-signs-Cooperative-Research-and-Development-Agreement-CRADA-with-US-National-Institute-on-Drug-Abuse-NIDA-to-cover-Phase-3-development-of-mavoglurant-in-cocaine-use-disorde.html

    GLOBENEWSWIRE
    08 Mar 2023
    Share Share